Many patients with type 2 diabetes have additional co-morbidities such as obesity and hypertension. Significant unmet needs exist as nearly half of treated patients remain uncontrolled on their current glucose-lowering regimen and even fewer are controlled across multiple parameters. In the past, treatments for type 2 diabetes have focused primarily on insulin-dependent mechanisms. An approach that acts independently of insulin may provide an option for adults with type 2 diabetes in helping manage their glucose levels.
About SGLT2 Inhibition
The renal SGLT system plays a major role in overall glucose balance in the body. Normally, the kidney filters 180g of glucose each day, and virtually all is reabsorbed back into circulation. Glucose reabsorbtion occurs in the proximal tubule of the kidney via the SGLT system. Selective inhibition of SGLT2 by an insulin independent mechanism of action facilitates the excretion of glucose and associated calories in the urine, thereby lowering blood glucose levels.
Bristol-Myers Squibb and AstraZeneca Collaboration
Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that dapagliflozin will receive regulatory approval or, if approved, that it will become a commercially successful product. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2009, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com
Contacts:
Media: Ken Dominski, Bristol-Myers Squibb, +1-609-252-5251,
ken.dominski@bms.com
Jim Minnick, AstraZeneca, +1-302-885-5135,
jim.minnick@astrazeneca.com
Investors: John Elicker, Bristol-Myers Squibb, +1-609-252-4611,
john.elicker@bms.com
Karl Hard, AstraZeneca, +44-20-7304-5322,
karl.hard@astrazeneca.com
Clive Morris, AstraZeneca, +44-20-7304-5084,
clive.morris@astrazeneca.com
Contacts: Media: Ken Dominski, Bristol-Myers Squibb, +1-609-252-5251, ken.dominski@bms.com; Jim Minnick, AstraZeneca, +1-302-885-5135, jim.minnick@astrazeneca.com; Investors: John Elicker, Bristol-Myers Squibb, +1-609-252-4611, john.elicker@bms.com; Karl Hard, AstraZeneca, +44-20-7304-5322, karl.hard@astrazeneca.com; Clive Morris, AstraZeneca, +44-20-7304-5084, clive.morris@astrazeneca.com
Andalucía
